朗华制药

The supplied evidence does not describe the brand 朗华制药. The only source provided is a NetEase/IT之家 news article about OpenAI releasing an Admin plugin for ChatGPT Work and Codex, which contains no information about a pharmaceutical company, its products, ownership, headquarters, or history. Because the name 朗华制药 is a Chinese-language pharmaceutical-style name and no official site, Wikipedia entry, or brand-sense source was supplied, this dossier cannot responsibly assert founding details, products, executives, or market position. The entry is therefore kept short and flagged for review; it should be re-enriched once a genuine official website, corporate registry record, or encyclopedic source about the company is available.

• 2026-08-26

  Viva Biotech Reports 2026 Interim Results[2]维亚生物发布2026中期业绩prnasia.com

  Reported: 2026-08-26

  Viva Biotech Holdings (1873.HK) reported interim results for the six months ended June 30, 2026, with total revenue of RMB 1,006.5 million, up 21.0% year on year, gross profit of RMB 341.7 million, up 0.7%, and gross margin of 34.0%. Net profit was RMB 100.9 million and adjusted non-IFRS net profit was RMB 128.3 million, both down from the prior-year period, mainly due to lower investment income, unfavorable foreign exchange movements and higher R&D expenses from new business initiatives. CRO revenue was RMB 405.1 million and Langhua Pharmaceutical CDMO revenue was RMB 601.4 million, up about 47.0% year on year.

• Unconfirmed

  Langhua Pharmaceutical Builds 400 Cubic Meters of New Capacity[2]维亚生物发布2026中期业绩prnasia.com

  Reported: 2026-08-26

  As of June 30, 2026, Langhua Pharmaceutical had total available production capacity of 860 cubic meters and was building an additional 400 cubic meters of capacity to serve future commercialization of new modalities. Its Taizhou factory had completed the design of a GMP peptide solid-phase synthesis production line and was about to begin installation.

1. 1OpenAI发布适用于ChatGPT Work和Codex的Admin插件163.com
2. 2维亚生物发布2026中期业绩prnasia.com